Diffusion-weighted Imaging Magnetic Resonance for Assessing Liver Fibrosis

Status Completed

Clinical Trial Summary

Several noninvasive radiological techniques have been investigated for the diagnosis of liver fibrosis and cirrhosis among patients with chronic infection with hepatitis B virus or hepatitis C virus. Diffusion-weighted magnetic resonance imaging (DW-MRI) is a particularly appealing method for the diagnosis of liver fibrosis. The aims of this study are to evaluate the accuracy of DW-MRI in patients with chronic viral hepatitis for determining the stage of liver fibrosis.

Clinical Trial Description

Among patients with chronic infection with hepatitis B virus or hepatitis C virus, evaluation of the stage of liver fibrosis is of major importance for determining prognosis and therapeutic decisions. Liver biopsy is a costly and invasive technique with associated mortality and morbidity. A typical biopsy fragment represents only 1/50,000 of the organ. Several noninvasive radiological techniques have been investigated for the diagnosis of liver fibrosis and cirrhosis. Diffusion-weighted magnetic resonance imaging (DW-MRI) is a particularly appealing method for the diagnosis of liver fibrosis. Because it is easy to implement, non-operator dependent, and process without the need for contrast agents. However, preliminary studies on small numbers of patients in which various hardware and sequencing profiles were used have reported inconsistent results for staging liver fibrosis with DW-MRI. The aims of this study are to evaluate correlation between stage of hepatic fibrosis and liver apparent diffusion coefficient (ADC) and normalized liver ADC with spleen assessed by DW-MRI in patients with chronic viral hepatitis B or C. Also, this study aim to evaluate factors that influence liver ADC and normalized liver ADC with spleen value for predicting the stage of liver fibrosis as well as to estimate the optimal cutoff values of DW-MRI for determining significant liver fibrosis (fibrosis stage ≥2) and advanced fibrosis (fibrosis stage ≥3). ;

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02682108
Study type	Interventional
Source	Mahidol University
Contact
Status	Completed
Phase	N/A
Start date	April 2014
Completion date	June 2016

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT05479721` - LITMUS Imaging Study
Not yet recruiting	`NCT05120557` - Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASH	N/A
Active, not recruiting	`NCT05473806` - Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Type 2 Diabetes	Phase 4
Not yet recruiting	`NCT06463223` - HIBOC = Hepatic Imaging Biomarkers in Obese Children
Not yet recruiting	`NCT03222167` - Open-Label Efficacy and Safety Study of the Elbasvir/ Grazoprevir Fixed Dose Combination Patients With Chronic HCV GT1b	Phase 3
Active, not recruiting	`NCT02344680` - Liver Fibrosis in Zambian HIV-HBV Co-infected Patients
Not yet recruiting	`NCT05567614` - Platelets Indices and Its Role to Predict Liver Fibrosis in Patients With Chronic Hepatitis B Infection
Active, not recruiting	`NCT05402371` - A Study to Evaluate the Efficacy and Safety of Rencofilstat in Subjects With NASH and Advanced Liver Fibrosis	Phase 2
Completed	`NCT03373396` - Impact of Chlordecone on Active Chronic Hepatitis	N/A
Recruiting	`NCT02569567` - Comparison of Smart-Shear Wave Elastography and Transient Elastography	N/A
Recruiting	`NCT05855031` - The Liver Care Trial	N/A
Completed	`NCT04493346` - Shear Wave Elastography
Completed	`NCT04380493` - The Use of the Transient Elastography Paediatric Probe, Compared to the M Probe, Indirect Biomarkers and Histology
Active, not recruiting	`NCT06315361` - DIAbetes and NAFLD
Not yet recruiting	`NCT03492879` - Non Invasive Electrical Impedance Technology (EIT) for Diagnosing Liver Diseases Severity	N/A
Not yet recruiting	`NCT06366425` - Screening for Chronic Liver Diseases in General Population	N/A
Recruiting	`NCT04442334` - The European NAFLD Registry
Recruiting	`NCT05692024` - COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER	Phase 1/Phase 2
Completed	`NCT03659058` - Impact of Ursodeoxycholic Acid, Silymarin, Antioxidants and Colchicine on Fibrosis Regression in HCV After SVR	N/A
Recruiting	`NCT05218538` - Liver Cirrhosis Diagnosis Prioritizing Algorithm Based on Electronic Health Records.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.